Quinolones for Treatment of Human Brucellosis: Critical Review of the Evidence from Microbiological and Clinical Studies

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2005 Dec 27

PMID 16377662

Citations 24

Authors

Matthew E Falagas

Ioannis A Bliziotis

Affiliations

Soon will be listed here.

Citing Articles

Motor polyradiculoneuropathy as an unusual presentation of neurobrucellosis: a case report and literature review.

Alikhani A, Ahmadi N, Frouzanian M, Abdollahi A BMC Infect Dis. 2024; 24(1):491.

PMID: 38745172 PMC: 11092037. DOI: 10.1186/s12879-024-09365-2.

Fulminant endogenous endophthalmitis caused by , a case report.

Hosseini S, Baghi M, Astaneh M, Motamed Shariati M Clin Case Rep. 2023; 11(11):e8200.

PMID: 38028096 PMC: 10643306. DOI: 10.1002/ccr3.8200.

Adaptation of Antimicrobial Susceptibility Testing to the ISO 20776 Standard and Validation of the Method.

Tscherne A, Mantel E, Boskani T, Budniak S, Elschner M, Fasanella A Microorganisms. 2022; 10(7).

PMID: 35889189 PMC: 9316112. DOI: 10.3390/microorganisms10071470.

The Characteristics, Prevalence, and Risk Factors of Drug-Induced Liver Injury Among Brucellosis Inpatients in Xinjiang, China.

Tuohutaerbieke M, Li X, Yin Y, Chen W, Wu D, Mao Z Front Pharmacol. 2021; 12:657805.

PMID: 34040524 PMC: 8141917. DOI: 10.3389/fphar.2021.657805.

Clinical manifestations and treatment outcomes of human brucellosis at a tertiary care center in Saudi Arabia.

Edathodu J, Alamri M, Alshangiti K, Alfagyh N, Alnaghmush A, Albaiz F Ann Saudi Med. 2021; 41(2):109-114.

PMID: 33818142 PMC: 8020648. DOI: 10.5144/0256-4947.2021.109.

References

Bodur H, Erbay A, Akinci E, Colpan A, Cevik M, Balaban N . Neurobrucellosis in an endemic area of brucellosis. Scand J Infect Dis. 2003; 35(2):94-7. DOI: 10.1080/0036554021000027000. View

Qadri S, Al-Sedairy S, Ueno Y . Antibacterial activity of lomefloxacin against Brucella melitensis. Diagn Microbiol Infect Dis. 1990; 13(3):277-9. DOI: 10.1016/0732-8893(90)90074-6. View

Kocagoz S, Akova M, Altun B, Gur D, Hascelik G . In vitro activities of new quinolones against Brucella melitensis isolated in a tertiary-care hospital in Turkey. Clin Microbiol Infect. 2002; 8(4):240-2. DOI: 10.1046/j.1469-0691.2002.00416.x. View

al-Eissa Y, Kambal A, Al-Nasser M, Al-Fawaz I, Al-Zamil F . Childhood brucellosis: a study of 102 cases. Pediatr Infect Dis J. 1990; 9(2):74-9. View

Tur B, Suldur N, Ataman S, Ozturk E, Bingol A, Atay M . Brucellar spondylitis: a rare cause of spinal cord compression. Spinal Cord. 2004; 42(5):321-4. DOI: 10.1038/sj.sc.3101571. View

Qadri S, Lee G, Ellis M . In vitro activity of lomefloxacin, a difluorinated quinolone, compared with other antimicrobials. Chemotherapy. 1991; 37(3):166-74. DOI: 10.1159/000238850. View

Tasova Y, Saltoglu N, Sahin G, Aksu H . Osteoarthricular involvement of brucellosis in Turkey. Clin Rheumatol. 2001; 18(3):214-9. DOI: 10.1007/s100670050087. View

Baykam N, Esener H, Ergonul O, Eren S, Celikbas A, Dokuzoguz B . In vitro antimicrobial susceptibility of Brucella species. Int J Antimicrob Agents. 2004; 23(4):405-7. DOI: 10.1016/j.ijantimicag.2003.09.024. View

Qadri S, Ayub A, Ueno Y, Saldin H . Susceptibility of Salmonella typhi and Brucella melitensis to the new fluoroquinolone rufloxacin (MF 934). Chemotherapy. 1993; 39(5):311-4. DOI: 10.1159/000239142. View

10.

Saltoglu N, Tasova Y, Inal A, Seki T, Aksu H . Efficacy of rifampicin plus doxycycline versus rifampicin plus quinolone in the treatment of brucellosis. Saudi Med J. 2002; 23(8):921-4. View

11.

Garcia-Sanchez E, Martinez I, Fresnadillo M, Garcia-Sanchez J, Garcia-Rodriguez J . In vitro activities of six new fluoroquinolones against Brucella melitensis. Antimicrob Agents Chemother. 1998; 43(1):194-5. PMC: 89049. DOI: 10.1128/AAC.43.1.194. View

12.

Qadri S, Lee G, Brodie L . Antibacterial activity of norfloxacin against 1700 relatively resistant clinical isolates. Drugs Exp Clin Res. 1989; 15(8):349-53. View

13.

Akova M, Uzun O, Akalin H, Hayran M, Unal S, Gur D . Quinolones in treatment of human brucellosis: comparative trial of ofloxacin-rifampin versus doxycycline-rifampin. Antimicrob Agents Chemother. 1993; 37(9):1831-4. PMC: 188077. DOI: 10.1128/AAC.37.9.1831. View

14.

Sturniolo G, Ricciardi F, Ruggeri P, Costantino G, Pellicano G, Bertuccio O . [Treatment of chronic brucellosis with ciprofloxacin. Personal experience]. Minerva Med. 1993; 84(4):187-90. View

15.

Khuri-Bulos N, Shaker K . Relapse of brucellosis following ofloxacin therapy. J Infect. 1991; 22(3):302-3. DOI: 10.1016/s0163-4453(05)80021-0. View

16.

Yorgancigil H, Yayli G, Oyar O . Neglected case of osteoarticular Brucella infection of the knee. Croat Med J. 2003; 44(6):761-3. View

17.

Bayindir Y, Sonmez E, Aladag A, Buyukberber N . Comparison of five antimicrobial regimens for the treatment of brucellar spondylitis: a prospective, randomized study. J Chemother. 2003; 15(5):466-71. DOI: 10.1179/joc.2003.15.5.466. View

18.

Qadri S, Halim M, Ueno Y, Abumustafa F, Postle A . Antibacterial activity of azithromycin against Brucella melitensis. Chemotherapy. 1995; 41(4):253-6. DOI: 10.1159/000239353. View

19.

Manosuthi W, Thummakul T, Vibhagool A, Vorachit M, Malathum K . Case report: Brucellosis: a re-emerging disease in Thailand. Southeast Asian J Trop Med Public Health. 2004; 35(1):109-12. View

20.

Colmenero J, Queipo-Ortuno M, Reguera J, Suarez-Munoz M, Morata P . Chronic hepatosplenic abscesses in Brucellosis. Clinico-therapeutic features and molecular diagnostic approach. Diagn Microbiol Infect Dis. 2002; 42(3):159-67. DOI: 10.1016/s0732-8893(01)00344-3. View